ARS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-in Capital | Accumulated Other Comprehensive Gain, Net | Accumulated Deficit | Total Stockholders’ Equity | |
| Balance at December 31, 2022 | 93,943,316 | $9 | $349,408 | $407 | $(76,938) | $272,886 |
| Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units | 2,471,647 | 1 | 6,899 | — | — | 6,900 |
| Stock-based compensation | — | — | 9,347 | — | — | 9,347 |
| Removal of retrospective insurance policy acquired in the Merger | — | — | (3,650) | — | — | (3,650) |
| Net loss and comprehensive loss | — | — | — | (358) | (54,365) | (54,723) |
| Balance at December 31, 2023 | 96,414,963 | $10 | $362,004 | $49 | $(131,303) | $230,760 |
| Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units | 1,539,209 | — | 3,017 | — | — | 3,017 |
| Stock-based compensation | — | — | 14,853 | — | — | 14,853 |
| Net income and comprehensive income | — | — | — | 171 | 7,998 | 8,169 |
| Balance at December 31, 2024 | 97,954,172 | $10 | $379,873 | $220 | $(123,305) | $256,798 |
The accompanying notes are an integral part of these financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.